Article in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Zeliha BirsinDepartment of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.
Hülya Odabaşı BükünDepartment of Medical Oncology, Faculty of Medicine, Bursa Uludağ University, 16400 Bursa, Türkiye.ORCID 0009-0000-5432-4981
İsmail NazlıDepartment of Medical Oncology, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, 34722 Istanbul, Türkiye.ORCID 0000-0001-7495-3996
Onur AlkanDepartment of Medical Oncology, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, 34722 Istanbul, Türkiye.ORCID 0000-0002-8558-1654
Murat GünaltılıDepartment of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.ORCID 0000-0001-6116-3936
Emir ÇermeDepartment of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.
Vali AliyevDepartment of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.
Selin CebeciDepartment of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.
Seda JeralDepartment of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.ORCID 0000-0002-6594-1712
Hamza AbbasovDepartment of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.ORCID 0000-0003-1227-9996
Türkkan EvrenselDepartment of Medical Oncology, Faculty of Medicine, Bursa Uludağ University, 16400 Bursa, Türkiye.ORCID 0000-0002-9732-5340
Çiğdem PapilaDepartment of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.
Nebi Serkan DemirciDepartment of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.
Özkan AlanDepartment of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.ORCID 0000-0002-6635-2012
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
Body Mass IndexBreast NeoplasmsAdultAgedErb-b2 Receptor Tyrosine KinasesFemaleHumansKaplan-Meier EstimateMiddle AgedPrognosisProportional Hazards ModelsRetrospective StudiesTrastuzumabERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabbody mass indexbreast cancerHER2-positivehormone receptorobesityoverall survivalprogression-free survival
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Is Body Mass Index a Prognostic Factor in Metastatic HER2-Positive Breast Cancer? A Real-World Multicenter Study. · full record | OpenQuestion